source
- Johnson & Johnson prepares $2.58 billion option to acquire Sail Biomedicines, expanding in-vivo CAR-T portfolioJohnson & Johnson announced a $2.58 billion option agreement to purchase Sail Biomedicines, a Flagship Pioneering‑backed biotech focused on in‑vivo CAR‑T therapies. The deal includes an upfront pa…
- Sanofi records €1B+ write-off, ends work on two immunology assetsSanofi booked over €1.03 billion in impairment charges in the second quarter largely due to an eczema drug termination, with its pipeline review leading to the wind-down of two other immunology dru…Endpoints · 1h ago↗ source